Project: Every Child for Younger Patients With Cancer

This study, called Project: Every Child, is collecting health information from children, adolescents, and young adults (up to 25 years old) who have cancer. The goal is to gather information over time to help doctors find better ways to treat and care for younger patients with various cancers, including adrenal gland pheochromocytoma, carcinoma in situ, central nervous system neoplasm, childhood immature teratoma, and childhood kidney neoplasm. Researchers will review medical charts and collect cytology specimens (samples of cells). The main goal is to see how many patients agree to have their biological samples stored for future research. This study is observational, meaning it watches and collects information rather than testing a new treatment. It aims to enroll 75,000 participants.

Study design: This is an observational study, meaning it collects health information without testing a new treatment. It plans to enroll 75,000 participants.
What's involved: You would undergo cytology specimen collection and have your medical data reviewed. Enrollment must happen within 6 months of initial disease presentation or other specific events.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint, consent to biobanking, is measured at Baseline. The study aims to collect information over time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Project: Every Child for Younger Patients With Cancer

Recruiting

Not specifiedUp to 25Observational

Children's Oncology Group

~75,000 participants

Updated 2026-08-25 on ClinicalTrials.gov

What's tested:Cytology Specimen Collection ProcedureMedical Chart Review

At a glance

Recruiting sites

253 of 279 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Number of patients who consented to biobanking

Measured over Baseline

Conditions

Adrenal Gland Pheochromocytoma

Carcinoma In Situ

Central Nervous System Neoplasm

Childhood Immature Teratoma

Childhood Kidney Neoplasm

Childhood Langerhans Cell Histiocytosis

Childhood Mature Teratoma

Congenital Mesoblastic Nephroma

Desmoid Fibromatosis

Ganglioneuroma

Lymphoproliferative Disorder

Malignant Neoplasm

Malignant Solid Neoplasm

Melanocytic Neoplasm

Myeloproliferative Neoplasm

Neoplasm of Uncertain Malignant Potential

Neuroendocrine Neoplasm

Stromal Neoplasm

Where it's being run

279 sites across 68 states

Michigan23

California19

Illinois19

Florida18

Texas17

New York15

Nevada13

Ohio8

Study leadership

Douglas S Hawkins · PRINCIPAL_INVESTIGATOR · Children's Oncology Group

Who to contact

Site Public Contact

[email protected]

205-638-9285

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem

Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority

Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:

All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one "1" (borderline), two "2" (carcinoma in situ) or three "3" (malignant)

All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant

All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant

The following other benign/borderline conditions:

Mesoblastic nephroma

Teratomas (mature and immature types)

Myeloproliferative diseases including transient myeloproliferative disease

Langerhans cell histiocytosis

Lymphoproliferative diseases

Desmoid tumors

Gonadal stromal cell tumors

Neuroendocrine tumors including pheochromocytoma

Melanocytic tumors, except clearly benign nevi

Ganglioneuromas

Subjects must be =\< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network \[NCTN\]) therapeutic study, for which there is a higher upper age limit

All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission

If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1

What this trial measures

Number of patients who consented to biobankingBaseline
The number of patients who agree to be in the Biobanking part of the study and have leftover tumor tissue and some normal blood, bone marrow, or other tissue saved for future research.

Trialytics